We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.59B
1-Year Est. Return
234.06%
This Fund
S&P 500
This Quarter
Est. Return
+1.82%
1 Year Est. Return
+234.06%
3 Year Est. Return
+822.97%
5 Year Est. Return
+865.41%
10 Year Est. Return
+12,585.11%
AUM
$1.3B
AUM Growth
-$473M
(-27%)
Cap. Flow
-$455M
Cap. Flow
% of AUM
-35.08%
Top 10 Holdings %
Top 10 Hldgs %
80.36%
Holding
41
New
–
Increased
2
Reduced
3
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Senti Biosciences Holdings
SNTI
|
+$13M |
| 2 |
Oric Pharmaceuticals
ORIC
|
+$5.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRNA
Verona Pharma
VRNA
|
+$173M |
| 2 |
TEM
Tempus AI
TEM
|
+$150M |
| 3 |
NextNav
NN
|
+$127M |
| 4 |
Geron
GERN
|
+$9.83M |
| 5 |
Sagimet Biosciences
SGMT
|
+$9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.44% |
| 2 | Consumer Staples | 6.6% |
| 3 | Industrials | 0.55% |
| 4 | Communication Services | 0.41% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
BuzzFeed
BZFD
$87.5M
| $5.35M | 0.41% |
2,512,103
-1,321,370
| -34% | -$3.16M |
|
|
IVA
27
Inventiva
IVA
$912M
| $4.3M | 0.33% |
1,462,586
| – | – |
|
|
SYBX
28
DELISTED
Synlogic
SYBX
| $3.62M | 0.28% |
2,922,772
| – | – |
|
29
X4 Pharmaceuticals
XFOR
$359M
| $3.54M | 0.27% |
499,560
| – | – |
|
|
ADAP
30
DELISTED
Adaptimmune Therapeutics
ADAP
| $3.36M | 0.26% |
17,079,778
| – | – |
|
|
INZY
31
DELISTED
Inozyme Pharma
INZY
| $2.22M | 0.17% |
2,437,689
| – | – |
|
|
OKUR
32
OnKure Therapeutics
OKUR
$119M
| $2.06M | 0.16% |
478,548
| – | – |
|
33
Marker Therapeutics
MRKR
$19.5M
| $2M | 0.15% |
1,625,678
| – | – |
|
|
ALLK
34
DELISTED
Allakos
ALLK
| $1.4M | 0.11% |
6,147,260
| – | – |
|
|
IMA
35
ImageneBio Inc
IMA
$55.8M
| $768K | 0.06% |
50,005
| – | – |
|
|
AFMD
36
DELISTED
Affimed
AFMD
| $320K | 0.02% |
442,648
| – | – |
|
37
Wheels Up
UP
$119M
| $107K | 0.01% |
5,306
| – | – |
|
|
38
Geron
GERN
$842M
| – | – |
-2,776,409
| Closed | -$9.83M |
|
39
Lexicon Pharmaceuticals
LXRX
$894M
| – | – |
-2,382,286
| Closed | -$1.76M |
|
|
40
NextNav
NN
$2.52B
| – | – |
-8,189,156
| Closed | -$127M |
|
|
41
Sagimet Biosciences
SGMT
$650M
| – | – |
-2,000,275
| Closed | -$9M |
|
Similar funds
ADL
CCP
ACM
SW
GCP
W
PIS
FWP
NEA Management Company's Q1 2025 Portfolio in Review
As of Q1 2025, NEA Management Company held 41 positions worth $1.3B, down 27% from $1.77B the previous quarter. Its ten largest holdings account for 80% of the portfolio.
NEA Management Company withdrew a net $455M in Q1 2025, closing 4 positions and reducing 3 holdings. Its most notable exit was NextNav, an estimated $127M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier, followed by Consumer Staples and Industrials.
Against the trend, NEA Management Company added an estimated $13M to Senti Biosciences Holdings.
- NEA Management Company added most to Senti Biosciences Holdings in Q1 2025, an estimated $13M increase.
- NEA Management Company's biggest Q1 2025 reduction was Verona Pharma, cutting an estimated $173M.
- NEA Management Company fully exited NextNav in Q1 2025, selling an estimated $127M.
- NEA Management Company's ten largest holdings make up 80% of its $1.3B portfolio in Q1 2025.
- NEA Management Company opened 0 new positions and closed 4 in Q1 2025.
- NEA Management Company's portfolio value fell 27% quarter-over-quarter to $1.3B.
Based on NEA Management Company's 13F filing for Q1 2025, filed 14 May 2025.